The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The long story of camptothecin: From traditional medicine to drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
von Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Hsiang, Y. H., & Liu, L. F. (1988) · PubMed · Cited by 841
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
A Model for the Mechanism of Human Topoisomerase I
Stewart, L., Redinbo, M. R., Qiu, X., Hol, W. G. J., & Champoux, J. J. (1998) · Science · doi:10.1126/science.279.5356.1534 · Cited by 717
Hertzberg, R. P., Caranfa, M. J., & Hecht, S. M. (1989) · Biochemistry · doi:10.1021/bi00437a018 · Cited by 551
Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., et al. (1991) · Journal of Medicinal Chemistry · doi:10.1021/jm00105a017 · Cited by 518
Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature
Venditto, V. J., & Simanek, E. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900243b · Cited by 452
Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., & Pommier, Y. G. (1989) · PubMed · Cited by 449
Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., YOKOKURA, T., Sawada, S., Miyasaka, T., & Mutai, M. (1987) · PubMed · Cited by 410
Pizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 359
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., & Kaufmann, S. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.647 · Cited by 353
Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., & Selawry, O. S. (1972) · PubMed · Cited by 312
Camptothecins: A Review of Their Chemotherapeutic Potential
Ulukan, H., & Swaan, P. W. (2002) · Drugs · doi:10.2165/00003495-200262140-00004 · Cited by 299
Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.
Moertel, C. G., Schutt, A. J., Reitemeier, R. J., et al. (1972) · PubMed · Cited by 274
Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).
Gottlieb, J. A., Guarino, A. M., CALL, J. B., Oliverio, V. T., & Block, J. B. (1970) · PubMed · Cited by 249
Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs
Wani, M. C., Ronman, P. E., Lindley, J. T., & Wall, M. E. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00179a016 · Cited by 234
The role of DNA topoisomerases in recombination and genome stability: A double-edged sword?
Wang, J. C., Caron, P. R., & Kim, R. A. (1990) · Cell · doi:10.1016/0092-8674(90)90002-v · Cited by 230
Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E., Lubejko, B. G., Chen, T. L., Rock, M. K., & Donehower, R. C. (1994) · PubMed · Cited by 194
Simon, J. A., Szankasi, P., Nguyen, D. K., Ludlow, C. L., Dunstan, H. M., Roberts, C. J., Jensen, E. L., Hartwell, L. H., & Friend, S. H. (2000) · PubMed · Cited by 193
Camptothecins New Anticancer Agents
Potmĕsil, M., & Pinedo, H. M. (1994) · Medical Entomology and Zoology · Cited by 179
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Nakada, T., Masuda, T., Naito, H., Yoshida, M., Ashida, S., Morita, K., Miyazaki, H., Kasuya, Y., Ogitani, Y., Yamaguchi, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.020 · Cited by 172
Kudoh, S., Fujiwara, Y., Takada, Y., Yamamoto, H., Kinoshita, A., Ariyoshi, Y., Furuse, K., & Fukuoka, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1068 · Cited by 169
Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., & Matsumoto, K. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685508 · Cited by 159
Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents
Wang, H., Morris-Natschke, S. L., & Lee, K. (1997) · Medicinal Research Reviews · Cited by 155
Current perspectives on camptothecins in cancer treatment
Dancey, J. E., & Eisenhauer, E. A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.362 · Cited by 150
Fulzele, D. P., & Satdive, R. K. (2004) · Journal of Chromatography A · doi:10.1016/j.chroma.2004.11.020 · Cited by 139
Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA-Damaging Drug
Beretta, G. L., Gatti, L., Perego, P., & Zaffaroni, N. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320120006 · Cited by 115
Homsi, J., Simon, G. R., Garrett, C. R., Springett, G. M., Conti, R. C. D., Chiappori, A., Münster, P. N., Burton, M. K., Stromatt, S. C., Allievi, C., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2821 · Cited by 103
Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin.
Thomsen, B., Mollerup, S., Bonven, B. J., Frank, R. W., Blöcker, H., NIELSEN, O. F., & Westergaard, O. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02436.x · Cited by 94
Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage
Kjeldsen, E., Mollerup, S. K., Thomsen, B., Bonven, B. J., Bolund, L., & Westergaard, O. (1988) · Journal of Molecular Biology · doi:10.1016/0022-2836(88)90462-7 · Cited by 84
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
Emerson, D. L., Besterman, J. M., Brown, H. R., Evans, M. G., Leitner, P., Luzzio, M. J., Shaffer, J. E., Sternbach, D. D., Uehling, D., & Vuong, A. (1995) · PubMed · Cited by 77
Topoisomerase I Interaction with SV4O DNA in the presence and absence of camptothecin
Jaxel, C., Kohn, K. W., & Pommier, Y. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.23.11157 · Cited by 57
Ko, A. H. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s88084 · Cited by 47
Lin, C., Lin, Y., Luh, F., Yen, Y., & Chen, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9878 · Cited by 46
Identification of repurposed small molecule drugs for chordoma therapy
Xia, M., Huang, R., Sakamuru, S., Alcorta, D. A., Cho, M.-H., Lee, D., Park, D. M., Kelley, M. J., Sommer, J., & Austin, C. P. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24596 · Cited by 36
Synthesis of CPT‐11 (Irinotecan Hydrochloride Trihydrate)
SAWADA, S., Yokokura, T., & MIYASAKA, T. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26372.x · Cited by 34
E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin
Dong, Y., Yang, H. L., & McMasters, K. M. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700565 · Cited by 29
Teng, L., Xie, J., Zhang, X., Teng, M., Yu, B., Yang, S., & Lee, R. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s103110 · Cited by 17
Topoisomerase I Inhibition by the Camptothecin Analog G1147211C
Besterman, J. M. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb26389.x · Cited by 16
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Natural Products in Cancer Therapy: Past, Present and Future
Huang, M., Lu, J.-J., & Ding, J. (2021) · Natural Products and Bioprospecting · doi:10.1007/s13659-020-00293-7 · Cited by 648
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
Chunarkar-Patil, P., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S., Dubey, R., Singh, H., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 390
Metadata
- Authors
- Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 27
- Issue
- 4
- Pages
- 701-707
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W2565205808
- Cited by
- 296
- References
- 44
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.